Search by Drug Name or NDC
NDC 51672-1363-03 Diclofenac sodium 30 mg/g Details
Diclofenac sodium 30 mg/g
Diclofenac sodium is a TOPICAL GEL in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Taro Pharmaceuticals U.S.A., Inc.. The primary component is DICLOFENAC SODIUM.
MedlinePlus Drug Summary
Diclofenac topical gel (Solaraze) is used to treat actinic keratosis (flat, scaly growths on the skin caused by too much sun exposure). Diclofenac is in a class of medications called nonsteroidal anti-inflammatory drugs (NSAIDs). The way diclofenac gel works to treat actinic keratosis is not known. Diclofenac is also available as a liquid (Pennsaid) and a gel (Voltaren) that are applied to the skin to treat arthritis pain. This monograph only gives information about diclofenac gel (Solaraze) for actinic keratosis. If you are using either of the products for osteoarthritis, read the monograph entitled diclofenac topical (osteoarthritis pain).
Related Packages: 51672-1363-03Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Diclofenac Topical (actinic keratosis)
Product Information
| NDC | 51672-1363 |
|---|---|
| Product ID | 51672-1363_bee6bcb3-bcd8-4e63-99f6-820aa20150c8 |
| Associated GPIs | 90374035304020 |
| GCN Sequence Number | 039826 |
| GCN Sequence Number Description | diclofenac sodium GEL (GRAM) 3 % TOPICAL |
| HIC3 | Q5N |
| HIC3 Description | TOPICAL ANTINEOPLASTIC PREMALIGNANT LESION AGENTS |
| GCN | 86831 |
| HICL Sequence Number | 003733 |
| HICL Sequence Number Description | DICLOFENAC SODIUM |
| Brand/Generic | Generic |
| Proprietary Name | Diclofenac sodium |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | diclofenac sodium |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | GEL |
| Route | TOPICAL |
| Active Ingredient Strength | 30 |
| Active Ingredient Units | mg/g |
| Substance Name | DICLOFENAC SODIUM |
| Labeler Name | Taro Pharmaceuticals U.S.A., Inc. |
| Pharmaceutical Class | Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Decreased Prostaglandin Production [PE], Nonsteroidal Anti-inflammatory Drug [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA206298 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 51672-1363-03 (51672136303)
| NDC Package Code | 51672-1363-3 |
|---|---|
| Billing NDC | 51672136303 |
| Package | 1 TUBE in 1 CARTON (51672-1363-3) / 50 g in 1 TUBE |
| Marketing Start Date | 2016-04-28 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |